**Potential treatment for Chikungunya discovered by Vivalis and A*STAR's SIgN**

2011-02-17

(Press-News.org) Singapore - Nantes (France) – February 15, 2011 (SGT) - The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS (NYSE Euronext: VLS), a French biopharmaceutical company, announced today the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment. The international team of scientists, coordinated by Dr Lucile Warter of SIgN, has published their groundbreaking discovery in the Journal of Immunology.

Chikungunya is prevalent in Africa, South Asia, and South-East Asia and is transmitted by the Aedes mosquito, the same mosquito that spreads dengue fever. In Singapore alone, over 1000 Chikungunya cases were reported over the period 2008-2010. Dr Warter and her collaborators used Humalex®, a VIVALIS technology platform designed to identify and generate fully human monoclonal antibodies, to develop two antibodies that could neutralize several Chikungunya strains in vitro by culturing immune cells from an individual who had developed resistance to Chikungunya. Monoclonal antibodies can be more potent and have fewer side effects than conventional small molecule drugs.

"The discovery of these antibodies is a big step forward in combating a disease that presently has no available vaccine or specific treatment. The use of VIVALIS' Humalex® was invaluable in helping us isolate the target antibodies from the cultured immune cells. We hope to further validate the use of these antibodies as a viable treatment for Chikungunya." said Dr Warter. She added that further testing in vivo would have to be carried out to validate the antibodies' performance as a potential treatment for Chikungunya.

"It is thanks to the successful synergy between industry and SIgN that the development of two antibodies against a disease that is on the rise has been accomplished. The combination of Humalex® technology, SIgN's expertise in human immunology, virology and molecular biology, and Singapore's location as a hub for Asia helped to speed up the selection, sequencing and characterization of the most potent antibody candidates. I am delighted to note that this breakthrough was achieved in less than a year from the start of the project", said SIgN Chairman Prof Philippe Kourilsky.

"The new platform used by SIgN for the generation of fully human monoclonal antibody is already providing excellent results, and we hope to generate a number of new fully human monoclonal antibodies that could be used as therapeutics," said SIgN Scientific Director Prof. Paola Castagnoli.

"The discovery of these new fully human monoclonal antibodies with strong neutralizing activities against the Chikungunya virus constitutes an an additional testimony of the efficiency of the Humalex® platform. Coming shortly after the signature of a major commercial agreement with sanofi Pasteur, the vaccine division of Sanofi Aventis, this discovery is a further validation of the power of VIVALIS Humalex® antibody discovery platform. It is a first milestone in our research partnership with SIgN and we expect to benefit from the excellent scientific input from SIgN scientists in the field of immunology in future collaborative programs", commented Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS.

###

Notes to the Editor:

Research publication: The research findings described in the press release can be found in the January 28 online issue of The Journal of Immunology under the title "Chikungunya Virus Envelope-Specific Human Monoclonal Antibodies with Broad Neutralization Potency".

Authors: Lucile Warter*, Chia Yin Lee*, Rekha Thiagarajan*, Marc Grandadam†,Serge Lebecque‡, Raymond T. P. Lin§, Sebastien Bertin-Maghit*, Lisa F. P. Ng*, Jean-Pierre Abastado*, Philippe Desprès†, Cheng-I Wang*,1 and Alessandra Nardin*,1

*Singapore Immunology Network, Agency for Science, Technology and Research, Singapore 138648; †Interactions Moléculaires Flavivirus-Hôtes and National Reference Center for Arboviruses, Institut Pasteur, Paris 75724 Cedex 15, France; ‡Laboratoire de Génétique Moléculaire, Signalisation et Cancer Unité Mixte de Recherche 5201, Centre Léon Bérard, Université Claude Bernard Lyon1/Hospices Civils de Lyon, Lyon 69008, France; and §National University of Singapore, Singapore 119074

1 C.W. and A.N. contributed equally to this work
Address correspondence and reprint requests to Dr. Lucile Warter, Singapore Immunology Network, Agency for Science, Technology and Research, 8A Biomedical Grove, #03-06 Immunos, Singapore 138648. E-mail address: lucile_warter@immunol.a-star.edu.sg

About the Singapore Immunology Network (SIgN)

The Singapore Immunology Network (SIgN), officially inaugurated on 15 January 2008, is a research consortium under the Agency for Science, Technology and Research (A*STAR)'s Biomedical Research Council. The mandate of SIgN is to advance human immunology research and participate in international efforts to combat major health problems. Since its launch, SIgN has grown rapidly and currently includes 200 scientists from 25 different countries of the world working under 20 renowned principal investigators. At SIgN, researchers investigate immunity during infections and inflammatory conditions including cancer and are supported by cutting edge technological research platforms and core services. Through this, SIgN aims to build a strong platform in basic human immunology research for better translation of research findings into clinical applications. SIgN also sets out to establish productive links with local and international institutions, and encourage the exchange of ideas and expertise between academic, industrial and clinical partners and thus contribute to a vibrant research environment in Singapore.

For more information about SIgN, please visit www.sign.a-star.edu.sg.

Contact
Joshua Tan (Mr)
Corporate Communications
Agency for Science, Technology and Research (A*STAR)
Tel: (65) 6826 6353 - Email: joshua_tan@a-star.edu.sg

About VIVALIS (www.vivalis.com)

VIVALIS (Euronext code: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. VIVALIS' expertise and intellectual property are exploited in three main areas:

1. EB66® Cell Line: VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, especially monoclonal antibodies with enhanced cytotoxic activity. VIVALIS receives upfront payment, clinical stage milestone payments and royalties on its licensees' net sales.

2. Humalex® platform VIVALIS proposes customized solutions for the discovery, development and production of fully Human monoclonal antibodies. VIVALIS receives upfront payment, clinical stage milestone payments and royalties on its licensees' net sales.

3. 3D-Screen platform VIVALIS performs discovery and early stage development of small molecule compounds identified with its proprietary 3D-Screen platform. The 3D-Screen platform is designed to identify molecules that alter the three-dimensional structure of a target protein. With 3D-Screen, VIVALIS is building a portfolio of proprietary products for the treatment of hepatitis-C virus infection and other indications. Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (ca. 1,500 employees), a worldwide leader in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Merck, CSL, Kaketsuken, Merial, Intervet, SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters.

VIVALIS
Listed on Euronext Paris – Compartment C of NYSE Euronext
Reuters: VLS.PA – Bloomberg: VLS FP
Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexe

This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including the risk factors described in the company's document de référence, changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts
VIVALIS
Franck Grimaud, CEO
Email: investors@vivalis.com
NewCap
Financial communications agency
Steve Grobet / Emmanuel Huynh
Tel.: +33 (0) 1 44 71 94 91
Email: vivalis@newcap.fr

This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including the risk factors described in the company's document de référence, changes in economic conditions, the financial markets or the markets in which the company operates.

END

ELSE PRESS RELEASES FROM THIS DATE:

Macho muscle cells force their way to fusion

2011-02-17

In fact, according to new research from Johns Hopkins, the fusion of muscle cells is a power struggle that involves a smaller mobile antagonist that points at, pokes and finally pushes into its larger, stationary partner using a newly identified finger-like projection. In a report published Nov. 29 in the Journal of Cell Biology, the researchers described experiments using fruit fly embryos to identify an invasive projection propelled by the rapid elongation of actin filaments as the main player in the cellular power struggle. "We found that two muscle cells don't simply ...

Hearing loss and dementia linked in study

2011-02-17

Seniors with hearing loss are significantly more likely to develop dementia over time than those who retain their hearing, a study by Johns Hopkins and National Institute on Aging researchers suggests. The findings, the researchers say, could lead to new ways to combat dementia, a condition that affects millions of people worldwide and carries heavy societal burdens. Although the reason for the link between the two conditions is unknown, the investigators suggest that a common pathology may underlie both or that the strain of decoding sounds over the years may overwhelm ...

Scientists warn against stifling effect of widespread patenting in stem cell field

2011-02-17

In an opinion piece published Feb. 10 in the journal Science, a team of scholars led by a Johns Hopkins bioethicist urges the scientific community to act collectively to stem the negative effects of the patenting and privatizing of stem cell lines, data and pioneering technologies. This means grappling with the ambiguity of several fundamental distinctions typically made in ethics, law and common practice, the experts insist. The team, led by Debra Mathews, Ph.D., M.A., of the Johns Hopkins Berman Institute of Bioethics, says failures to properly manage the widespread ...

UT researchers link algae to harmful estrogen-like compound in water

2011-02-17

University of Tennessee, Knoxville, researchers have found that blue-green algae may be responsible for producing an estrogen-like compound in the environment which could disrupt the normal activity of reproductive hormones and adversely affect fish, plants and human health. Previously, human activities were thought solely responsible for producing these impacts. Theodore Henry, an adjunct professor for UT Knoxville's Center for Environmental Biotechnology and faculty at the University of Plymouth, and his colleagues looked into blue-green algae, or cyanobacteria, and ...

Biomarker could make diagnosing knee injury easier, less costly, Stanford othopaedists say

2011-02-17

STANFORD, Calif. — A recently discovered biomarker could help doctors diagnose a common type of knee injury, according to a new study. A team of researchers led by Gaetano Scuderi, MD, clinical assistant professor of orthopaedic surgery at Stanford University School of Medicine and an orthopaedic surgeon at Stanford Hospital & Clinics, has confirmed that a particular protein complex appears in patients with painful meniscal tears. The finding, to be published Feb. 16 in The Journal of Bone and Joint Surgery, could be used to prevent needless surgery and to save billions ...

Dwarfism gene linked to protection from cancer and diabetes

2011-02-17

A 22-year study of abnormally short individuals suggests that growth-stunting mutations also may stunt two of humanity's worst diseases. Published in Science Translational Medicine, part of the Science family of journals, the study raises the prospect of achieving similar protection in full-grown adults by other means, such as pharmaceuticals or controlled diets. The international study team, led by cell biologist Valter Longo of the University of Southern California and Ecuadorian endocrinologist Jaime Guevara-Aguirre, followed a remote community on the slopes of the ...

Reflected glory

2011-02-17

Messier 78 is a fine example of a reflection nebula. The ultraviolet radiation from the stars that illuminate it is not intense enough to ionise the gas to make it glow — its dust particles simply reflect the starlight that falls on them. Despite this, Messier 78 can easily be observed with a small telescope, being one of the brightest reflection nebulae in the sky. It lies about 1350 light-years away in the constellation of Orion (The Hunter) and can be found northeast of the easternmost star of Orion's belt. This new image of Messier 78 from the MPG/ESO 2.2-metre telescope ...

Adherence course reduces hypertension

2011-02-17

A high proportion of patients with high blood pressure are failing to take their medication properly and would benefit clinically from a course of 'adherence therapy', according to new research from the University of East Anglia (UEA). High blood pressure – or hypertension – is one of the major cardiovascular diseases worldwide. It leads to stroke and heart disease and costs more than $300 billion each year. Around a quarter of the adult population is affected – including 10 million people in the UK. Around half of patients with hypertension fail to reduce their blood ...

Ultrasound fusion imaging provides comparable accuracy for bone, soft tissue tumors

2011-02-17

DETROIT – Biopsies using ultrasound fusion imaging for detecting bone and soft tissue cancers are safe, effective and just as accurate as conventional biopsy methods, according to a Henry Ford Hospital study. Researchers found that the ultrasound fusion imaging technique guides a needle biopsy with precise accuracy and ease, while making the biopsy experience more convenient for patients. Ultrasound fusion merges real-time ultrasound images with previously acquired computed tomography or magnetic resonance imaging scans, providing physicians with high resolution, life-like ...

Customized knee replacement depends on surgeon's skill, not implant design

2011-02-17

DETROIT – While the choices of knee implants are plentiful, the success of total knee replacement surgery still is dependent on the surgeon's skill, Henry Ford Hospital researchers say. Researchers found that utilizing a series of common but nuanced surgical techniques is far more important to customizing the fit of a patient's implant than the implant's design. The findings will be displayed at the annual meeting of the American Academy of Orthopaedic Surgeons Feb. 15-18 in San Diego. "Customized knee implants will not replace the need for precise, methodical surgical ...

Potential treatment for Chikungunya discovered by Vivalis and A*STAR's SIgN

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES:

**Potential treatment for Chikungunya discovered by Vivalis and A*STAR's SIgN**